We observed that combined treatment of trastuzumab with verteporfin significantly reduced pH3 expression (p = 1.2 × 10−4, Figure S9B) and increased c-casp3 expression (p = 7.2 × 10−5, Figure S9C) in vivo, compared to single treatment with trastuzumab, which correlated with a significant decrease in tumor proliferation and enhancement of apoptosis rates, respectively. The gene discussed is CASP3; the disease is neoplasm.